CD3-targeting GCAR gene therapy
/ Exuma Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 15, 2022
EXUMA Biotech to Present Preclinical Data from its Subcutaneous CAR-TaNK and In Vivo CAR Cell and Gene Therapy Programs at the American Association for Cancer Research Annual Meeting
(PRNewswire)
- "EXUMA Biotech, Corp...announced that preclinical data from its novel, subcutaneous CAR-TaNK therapy for hematological tumors, and in vivo engineered CAR gene therapy program (GCAR), will be presented in two posters at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, in New Orleans, LA."
Preclinical • Hematological Malignancies • Oncology
1 to 1
Of
1
Go to page
1